The maximum tolerated dose and biologic effects of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) in combination with irinotecan for patients with refractory solid tumors

By Choi Brian   Alberti Dona   Schelman William   Kolesar Jill   Thomas James   Marnocha Rebecca   Eickhoff Jens   Ivy S.   Wilding George   Holen Kyle  

Cancer Chemotherapy and Pharmacology, Vol. 66, Iss. 5, 2010-10 ,pp. : 973-980

Springer Publishing Company

Access to resources Recommend Favorite

Low dose methotrexate and vinblastine, given weekly to patients with desmoid tumours, is associated with major toxicity

By van der Hul René L.   Seynaeve Caroline   van Geel Bert N.   Verweij Jaap  

Sarcoma, Vol. 7, Iss. 3-4, 2003-01 ,pp. : 153-157

Informa Healthcare

Access to resources Recommend Favorite

Predicting the maximum-tolerated dose of PNU-159548 (4-demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin) in humans using CFU-GM clonogenic assays and prospective validation

By Moneta D.   Geroni C.   Valota O.   Grossi P.   de Jonge M.J.A.   Brughera M.   Colajori E.   Ghielmini M.   Sessa C.  

European Journal of Cancer, Vol. 39, Iss. 5, 2003-03 ,pp. : 675-683

Elsevier

Access to resources Recommend Favorite

Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro

By Jeong Seongwook   Woo Margaret   Flockhart David   Desta Zeruesenay  

Cancer Chemotherapy and Pharmacology, Vol. 64, Iss. 5, 2009-10 ,pp. : 867-875

Springer Publishing Company

Access to resources Recommend Favorite

Consensus Guideline for Use of Glucarpidase in Patients with High‐Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance

By  

The Oncologist, Vol. 23, Iss. 1, 2018-01 ,pp. : 52-61

John Wiley & Sons Inc

Access to resources Recommend Favorite